BioNTech (NASDAQ:BNTX) Releases Quarterly Earnings Results, Beats Expectations By $0.70 EPS

BioNTech (NASDAQ:BNTX) issued its earnings results on Monday. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70, RTT News reports. The business had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.90 EPS. BioNTech updated its FY 2025 guidance to EPS.

BioNTech Stock Performance

Shares of NASDAQ BNTX opened at $98.39 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech has a one year low of $76.53 and a one year high of $131.49. The business’s 50-day moving average price is $116.45 and its two-hundred day moving average price is $113.13. The company has a market capitalization of $23.59 billion, a P/E ratio of -46.85 and a beta of 0.30.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. decreased their price target on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research report on Tuesday, November 26th. Wells Fargo & Company started coverage on shares of BioNTech in a report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price for the company. Berenberg Bank started coverage on shares of BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target on the stock. Evercore ISI upgraded shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their price target for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. Finally, Morgan Stanley lowered their price objective on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average price target of $143.65.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.